Skip to main content
. 2021 Jun 18;12(1):378–393. doi: 10.1016/j.apsb.2021.06.005

Figure 6.

Figure 6

In vitro studies of co-formulations. (A) Cellular uptake of co-formulations (NT co-formulation = non-targeted co-formulation; co-formulation = targeted co-formulation) containing Rhodamine was assessed at 6 h using confocal microscopy (scale bar = 5 μm). The quantification was shown in Fig. S4. (B) Cellular uptake of co-formulations containing Rhodamine was assessed at 4 h using flow cytometry (BD). Data are presented as mean ± SD (n = 3). ∗P < 0.05 and ∗∗P < 0.01, relative to PBS. (C) Cell viability (%) of co-formulations at 24 h. Data are presented as mean ± SD (n = 3). ∗P < 0.05 and ∗∗P < 0.01, relative to free drugs. (D) Cell-free areas before and after treatment of co-formulations (12 h) were imaged and measured for the relative scratch area (%) (scale bar = 50 μm). Data are presented as mean ± SD (n = 3). ∗P < 0.05 and ∗∗P < 0.01, relative to free drugs. (E) The colony formation following treatment of co-formulations (4 weeks) (scale bar = 50 μm). Data are presented as mean ± SD (n = 3). ∗P < 0.05 and ∗∗P < 0.01, relative to free drugs.